The Top 5 Biosimilar Articles for the Week of September 1

Number 5: A 10-year prospective follow-up of 244 healthy stem cell donors found no new safety concerns with Sandoz’s filgrastim biosimilar, reinforcing its long-term safety for donor mobilization.

Number 4: A new biosimilar for aflibercept shows similar efficacy and safety in treating neovascular age-related macular degeneration (nAMD), enhancing patient access to treatment.

Number 3: Canadian study reveals no significant differences in remission outcomes between etanercept biosimilars and the originator, Enbrel, for rheumatoid arthritis patients.

Number 2: Alvotech, an Iceland-based biosimilar-focused biotech company, marked a significant financial milestone in the first half of 2025, swinging from a substantial loss to a net profit, driven by the strong commercial performance of its key biosimilar products.

Number 1: The competitive landscape for bone health treatments in the US has intensified with the FDA approval of Bildyos (denosumab-nxxp) and Bilprevda (denosumab-nxxp), biosimilars to Amgen’s reference products Prolia and Xgeva, respectively.